



The Rare Anaemias

a clinical challenge



WHAT IS A RARE ANAEMIA ?

1. ANAEMIA WITH A **PREVALENCE < 5 / 10.000 IN EUROPE**
2. NOT DUE TO **IRON DEFICIENCY**
3. **CONGENITAL** ORIGIN IN MORE THAN 80% OF CASES
4. **UNKNOWN** AETIOLOGY IN ABOUT 30% OF CASES
5. **KEY CLINICAL SIGN** OF MORE THAN 62 RARE DISEASES



THE RARE ANAEMIAS IN THE CONTEXT OF RARE DISEASES

- **BLOOD TRANSFUSIONS AND IRON CHELATING** ARE ,IN GENERAL, THE ONLY THERAPEUTIC OPTIONS
- **PREVENTIVE ACTIONS** TO REDUCE ITS FREQUENCY AND TO ACHIEVE AN EQUILIBRIUM BETWEEN MORBIDITY AND PATIENT'S QUALITY OF LIFE ARE FREQUENTLY REQUIRED (Newborn screening programs)
- **MORE THAN 500.000 CHILDREN**, WORLDWIDE, BORN WITH A RARE ANAEMIA , MAINLY DUE TO :
 - THALASAEMIA (Mediterranean Anaemia)
 - SICKLE-CELL DISEASE (Sickle-Cell Anaemia)





Co-funded by the Health
Programme of the European Union

THE ENERCA PROJECT

creating an **NETWORK** since 2002

Phase I (2002 – 2004)

- @ First network of experts
- @ Clear and concise information
- @ Protocols for diagnosis
- @ **Congenital anaemias only**

Phase II (2005 – 2008)

- @ Network Consolidation
- @ Haemoglobinopathies database
- @ Dissemination and awareness
- @ **Congenital and acquired anaemias**

Phase III (2009 – 2012)

- @ Guidelines
- @ Social awareness
- @ **White Book**
- @ Patient's empowerment

Phase IV (2013-2016) : ICT tools implementarion



Online e-health Platforms on rare anaemias



Co-funded by the Health
Programme of the European Union




www.enerca.org



THE ENERCA PROJECT (2002-2012)

ENERCA nourished by all the concepts and initiatives surrounding rare diseases developed in Europe along its 10 years of life





PILOT EUROPEAN REFERENCE NETWORKS FOR RARE DISEASES FINANCED BY THE EUROPEAN COMMISSION

	2007	2008	2009	2010	2011	2012	2013
ECORN CF		01/04/2007 - 31/03/2010					
Dyscerne		April 2007 - March 2010					
PAAIR		April 2007 - March 2010					
EPNET		01/04/2007 - 31/03/2010					
EN-RBD		April 2007 - March 2010					
PHL			01/08/2008 - 31/07/2011				
Neuroped			24/04/2008 - 23/04/2011				
Euro Histo Net			01/09/2008-31/08/2011				
TAG			01/12/2008 - 30/11/2011				
Care-NMD					01/05/2010 - 30/04/2013		
ENERCA							



ENERCA PROJECT

12 Associated Partners
14 Collaborating Partners
> 30 Affiliated Members

Over **90 health professionals**
from up to **18 European countries**
also including **Eastern countries**

STRATEGY : Identification of expert centres in rare anaemias



Executive Consortium



H.CLINIC
Spain
WP1/2/3



Coordination

e-Health

H. ERASME
Belgium
WP6



Patients

TIF
Cyprus
WP4

Etical & Legal issues

UPV
Spain
WP7



CHUM
France
WP5



Registry


Learning



ENERCA MAIN POLICY

To increase the **efficacy of diagnosis, treatment and follow up** of patients ...

To **reduce health inequalities** in the diagnosis and prevention of major rare anaemias




Helping the Doctor= Helping the Patient



How to reduce health inequalities ?



Moving forward the creation of a **European Reference Network (ERN)** in **Rare Anaemias (RAs)**



Prepared on the basis of three main issues

- **Medical & Technical**
- **Legal & Ethical**
- **Patients Expectations**

Available soon through ENERCA website



The White Book

Analysis of controversial issues in the three main aspects:

Discussion of results and preparing a report...

Final discussion and consensus proposal...




Directive 2011/24/EU on the application of patients' rights in cross-border healthcare



Patients' Expectations

Answers received from 415 patients from 14 European countries

1. Availability of transfusion



2. School teaching/working days lost annually due to the treatment

Question	Number of patients	Percentage
None	45	10.84%
1-5 days	37	8.91%
6-10 days	20	4.82%
11-15 days	48	11.57%
16 or more days	213	51.33%
No reply	52	12.53%



Patients' Expectations

3. Priorities according to patients

Question	% of "Strong support"
Coordinated team with experienced doctor in charge	71,1
Doctor who understands patients' needs	67,5
Discuss treatment plans	62,4
Experience / technical support for diagnosis and complications	61
Multidisciplinary care	60
To follow best practice guidelines	58
Continuity of care	52,5
Staff attention to patient concerns	50,6
Network of expert centres nationally	50,4



ENERCA Professional Platforms

The three professional Platforms are designed, developed and tested within the
ENERCA Website

**Registry
(Cyprus)**

**Learning
(France)**

**e-Health
(Belgium)**

www.enerca.org

Health professionals, Health Authorities and other

Patients



ENERCA website

enerca
European Network for Rare and Congenital Anaemias

Contact Intranet Translate

Search

About Enerca Anaemias Members & Centers Patient Associations Activities News & Agenda For Professionals

Welcome

ENERCA means easy access to a high quality information on rare anaemias for patients, citizens, health professionals, stakeholders, authorities and pharmaceutical industry.

News Agenda

March 17, 2014
Belgium, UK and Germany move forward in the fight against rare diseases
All three countries presented have recently presented their Plans and Strategies in the fight against rare diseases. This kind of documents organizing the fight against rare diseases in European countries are necessary to reach a more harmonized and effective clinical care.

February 24, 2014
ESH Interactive Poster Sessions from the Annual Meeting 2013, now online
The European School of Haematology (ESH) recently shared online the Interactive Poster Sessions from the Annual Meeting 2013, which was held in New Orleans, Louisiana. Watch these interesting sessions online and receive up to date knowledge on rare anaemias.

More RSS

For patients

- Do you have Anaemia?
- Find your center
- Know more about Anaemias
- Create your patient Association Profile

For professionals

- Flowchart
- MAC
- Find colleagues
- Create your profile

Subscribe the ENERCA Newsletter

Sign Up

Previous newsletters

Site map
Privacy statement
Terms of use
Legal statement

Copyright © 2002 - 2014 Enerca

Co-funded by the Health Programme of the European Union.

www.enerca.org

- ① Full use of RA-ERN services
- ① Reliable and updated information
- ① Training & Educational Material
- ① News and Agenda (Newsletter)
- ① Easy access to the new IT tools



Anaemias

- [Aceruloplasminemia](#)
- [Adenylate kinase deficiency](#)
- [Alpha-thalassaemia - trait or carrier](#)
- [Autosomal dominant sideroblastic anaemia](#)
- [Beta-thalassaemia - trait or carrier](#)
- [CDA with thrombocytopenia \(GATA 1 mutation\)](#)
- [Congenital acanthocytosis](#)
- [Congenital dyserythropoietic anaemia type II](#)
- [Delta Beta-thalassaemia](#)
- [DMT1- deficiency anaemia](#)
- [Fanconi anaemia](#)
- [GLRX5-related Sideroblastic anaemia](#)
- [Glucose-6-phosphate dehydrogenase deficiency](#)
- [Glutathione synthetase deficiency](#)
- [Haemoglobin D disease](#)
- [Haemoglobin H disease](#)
- [Haemoglobin M with anaemia](#)
- [Hereditary persistence of fetal haemoglobin](#)
- [Hereditary Stomatocytosis](#)
- [Hydrops fetalis](#)
- [Iron - refractory iron deficiency Anemia](#)
- [Adenosine deaminase increased activity -ADA-](#)
- [Aldolase deficiency](#)
- [Atransferrinemia](#)
- [Autosomal recessive sideroblastic anaemia](#)
- [Beta-thalassaemia major \(and intermedia\)](#)
- [Compound heterozygous sickling disorders](#)
- [Congenital dyserythropoietic anaemia type I](#)
- [Congenital dyserythropoietic anaemia type III](#)
- [Diamond- Blackfan-Anemia](#)
- [Familial hypoplastic anaemia](#)
- [Gamma-glutamyl-cysteine synthetase deficiency](#)
- [Glucose phosphate isomerase deficiency](#)
- [Glutathione reductase deficiency](#)
- [Haemoglobin C disease](#)
- [Haemoglobin E disease](#)
- [Haemoglobin Lepore](#)
- [Hereditary Elliptocytosis](#)
- [Hereditary Spherocytosis](#)
- [Hexokinase deficiency](#)
- [Imerslund-Gräsbeck-Syndrom](#)
- [Kearns-Sayre syndrome](#)

+ [Know.r](#)

Up to 62 Rare diseases with anaemia as key clinical symptom

Do you have Anaemia?

What is a rare anaemia?

Anaemia is a condition where the haemoglobin and the red blood cells are lower than normal. There are many types of anaemia, but only a few are rare.

Information is directly nourished from professionals and patients profiles

What is a rare anaemia?

According to the European Commission a disease is rare when its population frequency is less than 5 cases in 10,000 individuals.



Sickle cell anaemia

General info

Members & centers

Patient Associations

Enerca Documents

Scientific Publications

Useful links



Acronym: SCA

Synonym(s): Drepanocytosis

ORPHANET code: [232](#)

OMIM code: [603903](#)

ICD-10 code: D57.0

Include: Only HbS Homozygosity

Group: Structural haemoglobinopathies

Subgroup: Sickle cell disorders

Haemoglobin S and sickle cell disorders: are disorders of the haemoglobin, a major component of the red blood cells. Sickle cell disorders (SCD) are the consequence of the presence of an abnormal haemoglobin called haemoglobin S (Hb S). There are several forms of which the most frequent is due to haemoglobin S homozygosity, while compound heterozygosity lead to a more or less severe form: SC, SD-Punjab, SO-Arab, SB-thalassaemia.



What causes the disease and how common is it?

This is a genetic disease. It is linked to a mutation of the B-globin gene, encoding the β -globin chain, one of the components of haemoglobin (Hb). An individual can be heterozygous for the disorder (Hb AS individuals) when only one of the globin genes is mutated, or homozygous (Hb SS individuals), or compound heterozygotes HbSC, HbSD, HbSO-Arab, HbSB-thalassaemia individuals) when the two beta globin genes are affected. It is a frequent disorder in people originating from Africa, Middle-East, India, and the Mediterranean Basin. This is due to the fact that these areas were or are still infected with malaria and Hb S confers a relative protection against malaria.



What are the most frequent symptoms if I have the disease?

Sometimes red blood cells from patients with sickle cell disorders become sickle-shaped (crescent shaped), have difficulty passing through small blood vessels and are destroyed rapidly. This explains why people with a sickle cell disorder have anaemia (pallor) and jaundice (yellow color of the eyes); when the circulation is blocked by the sickle-shaped red blood



Welcome

ENERCA means easy access to a high quality information on rare anaemias for patients, citizens, health professionals, stakeholders, authorities and pharmaceutical industry.

Find your Centre

 News

 Agenda



January 22nd 2013

Summary report of the 6th Meeting of the EUCERD

The two-day meeting was the opportunity to tackle a number of priority subjects, including the elaboration of the EUCERD Recommendations on European Reference Networks for Rare Diseases, and the proposal from the European Commission to create an EU platform for rare disease registration. **ENERCA participated in the sessions presenting its 10 years of experience.**



January 17th 2013

Become a Friend of the Rare Disease Day

On 28 February, the entire rare disease community worldwide will converge to raise awareness for rare diseases and the millions of people affected. **ENERCA has already signed up as a "Friend of Rare Disease Day"**. This initiative has been created to give visibility to those who want to do something to raise awareness for rare diseases. The whole campaign is coordinated by EURORDIS at the international level and the National Alliances of Patient Organisations at the National level.



For patients

- [Find your center](#)
- [Know more about Anaemias](#)
- [Do you have Anaemia?](#)
- [Create your patient Association Profile](#)



For professionals

- [Flowchart](#)
- [MAC](#)
- [Find colleagues](#)
- [Create your profile](#)

Subscribe the ENERCA Newsletter

Sign Up >

● [Previous Newsletter](#)



Sickle cell anaemia

General info	Members & centers	Patient Associations	Enerca Documents	Scientific Publications	Useful links
--------------	-------------------	----------------------	------------------	-------------------------	--------------



Germany

HAMBURG

GESUNDHEITZENTRUM MAX-BRAUER-ALLEE
Max-Brauer-Allee 52 - 22765 Hamburg

BERLIN

CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN: KLINIK FÜR PÄDIATRIE MIT SCHWERPUNKT ONKOLOGIE/HÄMATOLOGIE/KMT
Augustenburger Platz 1 - 13353 Berlin

 Stephan Lobitz, Dr.

HEIDELBERG


ZENTRUM FÜR KINDER- UND JUGENDMEDIZIN HEIDELBERG
INF 430 - 69120 Heidelberg

 Hermann Heimpel, Professor  Joachim Kunz, Dr.

FREIBURG

Members & Centers New Member / Center





Professor Hermann Heimpel

Physician

Center: [Zentrum für Kinder- und Jugendmedizin Heidelberg](#)

Address: INF 430 69120 Heidelberg • Germany

Clinical hematology in general, morphology of hematopoiesis, aplastic anemia, MDS, iron metabolism, hemolytic anemias, congenital dyserythropoietic anemias, stem cell transplantation, drug induced blood disorders.

Medical education.

Documents

- › [Congenital Dyserythropoietic Anemias: "New observations, and practical aspects of diagnosis and therapy" \(2007\)](#)
- › [Unstabiles Hämoglobin](#)
- › [Hämoglobin S und Sichelzellkrankheiten](#)
- › [Hämoglobin Lepore](#)
- › [Hämoglobin E](#)
- › [Beta-Thalassämie – leichte Form oder Trägerstatus \(Thalassaemia minor\)](#)
- › [Bei der Hämoglobin C-Krankheit liegt](#)
- › [Hämoglobin M mit Anämie](#)
- › [Hämoglobin H-Krankheit](#)



Sickle cell anaemia

- General info
- Members & centers
- Patient Associations
- Enerca Documents
- Scientific Publications
- Useful links



Cyprus

NICOSIA

THALASSAEMIA INTERNATIONAL FEDERATION

P.O. Box 28807 - 2007 Strovolos Nicosia



France

STRASBOURG

DORYS

1a place des orphelins - 67200 Strasbourg



Italy

GENOVA

ASSOCIAZIONE LIGURE THALASSEMICI ONLUS

C/O E.O. OSPEDALI GALLIERA VIA VOLTA 8 - 16128 GENOVA

Members & Centers

New Member / Center





Thalassaemia
International
Federation



Thalassaemia International Federation

E-mail: thalassaemia@cytanet.com.cy

Phone: +357-22-319-129

Fax: +357-22-314-552

Website: <http://www.thalassaemia.org.cy>

Address: P.O. Box 28807, 2007 Strovolos Nicosia • CYPRUS

Contact Person: Dr. Androulla Eleftheriou Executive Director

Thalassaemia International Federation (TIF) is a non-profit, non-governmental patient-driven organisation founded in 1986 and working in official relations with the World Health Organization (WHO) since 1996. TIF is an umbrella organisation involving 108 national thalassaemia associations and other members from over 60 countries across the world.

Diseases

- › [Compound heterozygous sickling disorders](#)
- › [Haemoglobin C disease](#)
- › [Haemoglobin D disease](#)
- › [Haemoglobin E disease](#)
- › [Haemoglobin M with anaemia](#)
- › [Sickle cell anaemia](#)



And more...



[Contact](#) [Intranet](#) [Translate](#)

[About Enerca](#) [Anaemias](#) [Members & Centers](#) [Patient Associations](#) **[Activities](#)** [News & Agenda](#) [For Professionals](#)

[Home](#) [Activities](#) **[Educational material](#)**

Educational material

Rare anaemias definitions

Collaboration

Education material

Training

Newsletters


All About Thalassemia



The Thalassemia International Federation (TIF) dedicates this [book](#) to all the children in the world born with Thalassemia. To their indomitable will to survive, their inspiring fight against the disease, their beautiful dreams of a good life and a bright future. TIF is a partner of ENERCA and its educational publications provide concise, up-to-date information on all aspects of thalassemia, from prevention to clinical management.

ENERCA video about haemoglobinopathies and children

Haemoglobinopathies are inherited blood disorders that reduce the production of haemoglobin, a substance within red blood cells that carries oxygen through all the body. Haemoglobinopathies are inherited illnesses that can pass from parents to their children. **Get informed!** All you need to do is a haemogram and a haemoglobins study. Ask your family doctor. Even parents who are both carriers of a haemoglobinopathy can have a healthy family together.



The video has been designed by ENERCA professionals to explain the importance of prenatal screenings. It is available also in [Spanish](#), [Portuguese](#), [Italian](#) and [French](#) at [Vimeo](#).

Educational Material



Video on prevention....genetic counseling...

English, Spanish
Portuguese,
Italian, French and more



BUT
HAEMOGLOBINOPATHIES

CAN PASS ON FROM
PARENTS TO THEIR CHILDREN

Welcome

ENERCA means easy access to a high quality information on rare anaemias for patients, citizens, health professionals, stakeholders, authorities and pharmaceutical industry.

 News

 Agenda



January 22nd 2013

Summary report of the 6th Meeting of the EUCERD

The two-day meeting was the opportunity to tackle a number of priority subjects, including the elaboration of the EUCERD Recommendations on European Reference Networks for Rare Diseases, and the proposal from the European Commission to create an EU platform for rare disease registration. **ENERCA participated in the sessions presenting its 10 years of experience.**



January 17th 2013

Become a Friend of the Rare Disease Day

On 28 February, the entire rare disease community worldwide will converge to raise awareness for rare diseases and the millions of people affected. **ENERCA has already signed up as a "Friend of Rare Disease Day"**. This initiative has been created to give visibility to those who want to do something to raise awareness for rare diseases. The whole campaign is coordinated by EURORDIS at the international level and the National Alliances of Patient Organisations at the National level.



For patients

- [Find your center](#)
- [Know more about Anaemias](#)
- [Do you have Anaemia?](#)
- [Create your patient Association Profile](#)



For professionals

- [Flowchart](#)
- [MAC](#)
- [Find colleagues](#)
- [Create your profile](#)

Subscribe the ENERCA Newsletter

[Sign Up >](#)

● [Previous Newsletter](#)

Flowchart



Diagnosis Flowchart



Anaemia Diagnosis

The flowchart provided here intends to be guidance for a first diagnostic approach for rare congenital anaemias in adults. The ENERCA team doesn't lay any claim to its completeness. Some haematological parameters should be introduced before the flowchart can start. The normal reference values for haematological parameters have been partially obtained from Dacie and Lewis' PRACTICAL HAEMATOLOGY, 10th Edition 2006, edited by S.M. Lewis, B.J. Bain and I. Bates and are given as follows:

Haemoglobin:	Woman:	120-150 g/L
	Man:	130-170 g/L
Reticulocytes:	Woman/Man:	50-100 x 10 ⁹ /L
Mean cell volume:	Woman/Man:	80-100 fL (83-101 fL in Dacie and Lewis' <i>Practical Haematology</i>)

Woman

Man

Haemoglobin (Hb)	<input type="text"/>	g/L
Reticulocytes (Retics)	<input type="text"/>	x10 ⁹ /L
Mean cell volume (MCV)	<input type="text"/>	fL

Calculate



ENERCA for Professionals



Anaemia Diagnosis

The flowchart provided here intends to be guidance for a first diagnostic approach for rare congenital anaemias in adults. The ENERCA team doesn't lay any claim to its completeness. Some haematological parameters should be introduced before the flowchart can start. The normal reference values for haematological parameters have been partially obtained from Dacie and Lewis' PRACTICAL HAEMATOLOGY, 10th Edition 2006, edited by S.M. Lewis, B.J. Bain and I. Bates and are given as follows:

Haemoglobin:	Woman:	120-150 g/L
	Man:	130-170 g/L
Reticulocytes:	Woman/Man:	50-100 x 10 ⁹ /L
Mean cell volume:	Woman/Man:	80-100 fL (83-101 fL in Dacie and Lewis' <i>Practical Haematology</i>)

Result

No anaemia has been identified

<input type="radio"/> Woman	Haemoglobin (Hb)	<input type="text" value="145"/> g/L
<input checked="" type="radio"/> Man	Reticulocytes (Retics)	<input type="text" value="67"/> x10 ⁹ /L
	Mean cell volume (MCV)	<input type="text" value="89"/> fL

Calculate



Diagnosis Flowchart



Anaemia Diagnosis

The flowchart provided here intends to be guidance for a first diagnostic approach for rare congenital anaemias in adults. The ENERCA team doesn't lay any claim to its completeness. Some haematological parameters should be introduced before the flowchart can start. The normal reference values for haematological parameters have been partially obtained from Dacie and Lewis' PRACTICAL HAEMATOLOGY, 10th Edition 2006, edited by S.M. Lewis, B.J. Bain and I. Bates and are given as follows:

Haemoglobin:	Woman:	120-150 g/L
	Man:	130-170 g/L
Reticulocytes:	Woman/Man:	50-100 x 10 ⁹ /L
Mean cell volume:	Woman/Man:	80-100 fL (83-101 fL in Dacie and Lewis' <i>Practical Haematology</i>)

Woman Man

Haemoglobin (Hb)	<input type="text" value="115"/> g/L
Reticulocytes (Retics)	<input type="text" value="90"/> x10 ⁹ /L
Mean cell volume (MCV)	<input type="text" value="76"/> fL

Calculate



Diagnosis Flowchart



Anaemia Diagnosis

The flowchart provided here intends to be guidance for a first diagnostic approach for rare congenital anaemias in adults. The ENERCA team doesn't lay any claim to its completeness. Some haematological parameters should be introduced before the flowchart can start. The normal reference values for haematological parameters have been partially obtained from Dacie and Lewis' PRACTICAL HAEMATOLOGY, 10th Edition 2006, edited by S.M. Lewis, B.J. Bain and I. Bates and are given as follows:

Haemoglobin:	Woman:	120-150 g/L
	Man:	130-170 g/L
Reticulocytes:	Woman/Man:	50-100 x 10 ⁹ /L
Mean cell volume:	Woman/Man:	80-100 fL (83-101 fL in Dacie and Lewis' <i>Practical Haematology</i>)

Woman

Man

Haemoglobin (Hb)	<input type="text" value="115"/> g/L
Reticulocytes (Retics)	<input type="text" value="90"/> x10 ⁹ /L
Mean cell volume (MCV)	<input type="text" value="76"/> fL

Calculate

Result

Anemia has been identified

For further investigation of rare anaemias be aware that the more frequent causes of anaemia in clinical practice should be excluded.

These could be drug ingestion, chemotherapy, alcohol intake, haemorrhage of different origin, radiation therapy, chronic diseases (rheumatic arthritis) and any other causes of secondary anaemia.

[See the Flowchart](#)




Diagnosis Flowchart



Anaemia Diagnosis

◀ [Anaemia Diagnosis](#)

Woman Haemoglobin (Hb) **115** g/L Reticulocytes (Retics) **90** g/L Mean cell volume (MCV) **76** g/L



And more...

**Free Webcasting
trainings courses**



enerca
European Network for Rare and Congenital Anaemias

Contact Intranet Translate

Search


About Enerca Anaemias Members & Centers Patient Associations **Activities** News & Agenda For Professionals

Home Activities Training **ESH Annual Meeting 2013**

Training

Investigators involved in groundbreaking researches present their findings

Interactive Poster Sessions from the ESH Annual Meeting 2013

 The Curriculum in Iron Metabolism & Related Disorders

 ESH EUROPEAN SCHOOL OF HAEMATOLOGY

In this [ESH webcast](#), investigators involved in groundbreaking studies about treatment regimens to reduce iron overload present their research findings and discuss the implications of their work for clinical practice.

Learning Objectives

- Evaluate the efficacy and safety of various chelator monotherapy and combination regimens, particularly in reducing cardiac and liver iron overload.
- Assess the efficacy of the use of chelation therapy in lower-risk myelodysplastic syndromes patients in order to determine the appropriateness of chelation therapy in your patients.
- Evaluate your adult sickle cell disease patients for iron overload and the possible need for iron chelation therapy.

[Watch it now!](#) (The activity requires a free registration)

[Site map](#)
[Privacy statement](#)
[Terms of use](#)
[Legal statement](#)

 IDIBAPS Institut d'Investigacions Biomèdiques August Pi i Sunyer

 CLÍNIC BARCELONA Hospital Universitari

 EURODIS European Rare Diseases Europe

 FEDER Federación Española de Enfermedades Raras

Copyright © 2002 - 2014 Enerca

Co-funded by the Health Programme of the European Union





ENERCA for Professionals

and more...

European Symposium on Rare Anaemias in collaboration with patients



4th EUR
3rd Bulgarian Symp



ON RARE ANAEMIAS


1st Italian thalassaemia meeting for patients and health professionals

15th -16th November 2013
Ferrara • Italy




The new ongoing Project: e-ENERCA

The patient at the centre of the sanitary ecosystem



Our mission is to **enhance the communication between healthcare professionals and patients; optimize prevention and monitoring processes and empower the patient.** Patients understand they are jointly responsible for their health and wellbeing, at the same time they receive a more personalized care.


**Information & Communication
TOOLS**



PATIENT



HEALTHCARE
PROFESSIONAL



INDUSTRY



PUBLIC AND PRIVATE
HEALTH SYSTEM



The three main reasons for e-health platforms

@ Poor **implementation of data collection** and analysis systems

→ **e-Registry**

@ Great **variability across Europe** to access certified and updated information

→ **e-Learning**

@ Deep **inequalities among countries** for diagnosis, prevention and clinical care of patients

→ **Telemedicine**



e-Registry: The challenge of epidemiology in rare anaemias

Some rare anaemias are not so rare: **Haemoglobinopathies**



- @ **Haemoglobinopathies** are today the most common genetic disorders in Europe.
- @ **Over 330,000 affected children** with major haemoglobinopathies are born worldwide each year.
- @ **1% of couples are at risk** of having a newborn with a severe syndrome.
- @ There are **poor data** on their precise prevalence, overall burden and trends.




e- ENERCA action for registry

*Androulla Eleftheriou (TIF)
Michael Angastiniotis(TIF)
(Cyprus)*

Main targets

- @ Inventory of **expert centres**
- @ Electronic record of **health data**
- @ Epidemiological **surveillance**
- @ Relevant **clinical information**



e-Learning: The challenge of knowledge in rare anaemias



**Patient's global
management
differs between
countries**

e-ENERCA action for education

*Patricia Aguilar (CHUM)
(France)*

Main targets

- @ Harmonization of **medical CV**
- @ Continuing **medical education**
- @ On-line modules for **teaching (*)**
- @ **e-learning** modules:
 - Training courses and workshops
 - Recommendations
 - Self training/self assessment
 - Interaction with experts (link-Telemedicine)


*** Complementary to on-site training modules**



http://www



Telemedicine: The challenge of diagnosis in rare anaemias



- @ About 30% of rare anaemias remain **undiagnosed or misdiagnosed**
- @ Treatment, genetic counselling and/or prognosis are **missing or incomplete**
- @ Scarce expertise in diagnosis creates **patient's and family anxiety**



e-ENERCA action for tele medicine

*Béatrice Gulbis (ERASME)
(Belgium)*

Main targets

- ① Increase **communication and sharing** of clinical knowledge
- ① Promote experts to share **on-line discussions**
- ① Allow an earlier and more accurate **diagnosis** and **patients follow-up**
- ① Facilitate **research** by storing large volume of data and images
- ① Decrease **health care costs**



ENERCA challenge

for ERN long term sustainability (1)



- ② National recognition of centers of expertise
- ② RA-ERN recognition by European Commission
- ② National and European economical support



ENERCA challenge

for ERN long term sustainability(2)

Main Targets

- ① Promote the recognition of **Centres of Expertise** on RAs and the **RA-ERN**
- ① Entry into force of the **Directive 2011/24/EU** on the application of patients' rights in cross-border healthcare.



e-ENERCA action for sustainability

Carlos Romeo (UPV/EHU)

Pilar Nicolas (UPV/EHU)

- 
- Identification of key players in each country:
 - Responsible person of a medical center
 - National Authority involved in the national plans for RD
 - Professional involved in RA diagnosis and management.
 - Presentation of the **ENERCA White Book** Recommendations for recognition of Centres of Expertise



e ENERCA :

A highway to the future



NOW:
ENERCA offers a solid platform to
develop multidisciplinary IT
initiatives for tackling rare
anaemias...



Rare Disease Day®





Co-funded by the Health
Programme of the European Union



www.enerca.org



Thank You!!!

ENERCA Coordinator Group

Head of Project – **Joan Lluís Vives Corrons**
(jlives@enerca.org)

Project Manager - **María del Mar Mañú**
(maria.manu@enerca.org)

Project Assistant - **Laura Olaya Costa**
(laura.olaya@enerca.org)



Unitat d'Eritropatologia

IDIBAPS

Hospital Clínic, University of Barcelona
c/ Villarroel 170 - 080036-Barcelona

Phone: +34 934515950

enerca@enerca.org

